Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABSK 043 (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Abbisko Therapeutics

    • Most Recent Events

    • 24 Oct 2023 Preliminary Results (As of February 2023, n=19) assessing the safety, tolerability, PK, PD, and preliminary efficacy of ABSK043 presented at the 48th European Society for Medical Oncology Congress
    • 16 Oct 2023 According to an Abbisko Therapeutics media release, data from this study will be presented at the 2023 European Society for Medical Oncology(ESMO) annual meeting to be held in Spain, from October 20 to 24, 2023.
    • 20 Apr 2022 Starting dose for escalation phase changed from 25 mg to 200 mg. Cohort 3 on 800mg will be switched to 400mg BID.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top